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Summary
 
An intact chemotactic response is vital for leukocyte trafficking and host defense. Opiates are
known to exert a number of immunomodulating effects in vitro and in vivo, and we sought to
determine whether they were capable of inhibiting chemokine-induced directional migration
of human leukocytes, and if so, to ascertain the mechanism involved. The endogenous opioid
met-enkephalin induced monocyte chemotaxis in a pertussis toxin–sensitive manner. Met-
enkephalin, as well as morphine, inhibited IL-8–induced chemotaxis of human neutrophils and
macrophage inflammatory protein (MIP)-1
 
a
 
, regulated upon activation, normal T expressed
and secreted (RANTES), and monocyte chemoattractant protein 1, but not MIP-1
 
b
 
–induced
chemotaxis of human monocytes. This inhibition of chemotaxis was mediated by 
 
d
 
 and 
 
m
 
 but
not 
 
k
 
 G protein–coupled opiate receptors. Calcium flux induced by chemokines was unaf-
fected by met-enkephalin pretreatment. Unlike other opiate-induced changes in leukocyte
function, the inhibition of chemotaxis was not mediated by nitric oxide. Opiates induced
phosphorylation of the chemokine receptors CXCR1 and CXCR2, but neither induced inter-
nalization of chemokine receptors nor perturbed chemokine binding. Thus, inhibition of
chemokine-induced chemotaxis by opiates is due to heterologous desensitization through
phosphorylation of chemokine receptors. This may contribute to the defects in host defense
seen with opiate abuse and has important implications for immunomodulation induced by sev-
eral endogenous neuropeptides which act through G protein–coupled receptors.
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L
 
ong-term abuse of opiates results in immune defects,
including impaired NK cell activity and altered CD4
 
1
 
and CD8
 
1
 
 T cell numbers (1), and it has been implicated as
a contributing factor in HIV infection (2). In animal mod-
els, parenteral use of opiates has been demonstrated to in-
hibit mitogenic and effector cell responses in B and T cells
(3, 4), cellular immunity (5), phagocytosis by neutrophils
and macrophages (6, 7), tumor cell suppression (6, 7), and
cytokine production (8). Morphine inhibits monocyte and
neutrophil functions through the physiologically defined
 
m
 
3
 
 opiate receptor (9, 10); indeed, binding sites and protein
expression for 
 
d
 
 and 
 
k
 
 subclasses of G protein–coupled opi-
ate receptors (11, 12), in addition to gene expression of 
 
d
 
,
 
k
 
, and 
 
m
 
 subclasses (13–15), have been described in leuko-
cytes.
Chemokines are a large family of chemotactic cytokines
that mediate their effects on leukocytes through a number
of G protein–coupled, seven transmembrane–spanning
(STM)
 
1
 
 receptors (16). Although there is apparent redun-
dancy in the ligand binding characteristics of these chemokine
receptors, specificity is provided by patterns of receptor and
G protein expression, ligand potency, and levels of receptor
 
1
 
 
 
Abbreviations used in this paper:
 
 CCR, CC chemokine receptor; CXCR,
CXC chemokine receptor; CTOP, cys
 
2
 
, tyr
 
3
 
, orn
 
5
 
, pen
 
7
 
 amide;
DAMGO, [
 
D
 
-ala
 
2
 
,
 
N
 
-me-phe-gly5(ol)]-enkephalin; MCP, monocyte
chemoattractant protein; MIP, macrophage-inflammatory protein; NAP,
neutrophil-activating peptide; NO, nitric oxide; RANTES, regulated
upon activation, normal T expressed and secreted; STM, seven trans-
membrane–spanning.
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desensitization. Interactions among STM receptors are com-
plex (17): in a process known as receptor cross-regulation,
or heterologous desensitization, thrombin receptor activa-
tion has been shown to cause phosphorylation of several
chemoattractant receptors, including the IL-8 receptor
CXCR1, the C5a receptor, and the receptor for platelet-
activating factor, but not that for FMLP (18). Such cross-
regulation does not occur between all classes of STM re-
ceptors; for example, 
 
a
 
1
 
-adrenergic receptors are unable to
desensitize chemoattractant receptors (19). We have shown
recently that homologous desensitization through phos-
phorylation of the IL-8 receptor CXCR2 occurs in re-
sponse to its native ligands IL-8 and neutrophil-activating
peptide (NAP)-2 (20). Together, these findings led us to
the hypothesis that the impairment of leukocyte functions
mediated by opiates may involve inhibition of chemokine
effects based on cross-regulation, resulting in phosphoryla-
tion and hence to heterologous desensitization of chemo-
kine receptors. The studies reported here show that opiates,
acting through 
 
d
 
 and 
 
m
 
 subclasses of opiate receptors ex-
pressed on human monocytes and neutrophils, are capable
of inhibiting subsequent migratory responses to chemokines,
and that this process of heterologous desensitization or trans-
deactivation is associated with phosphorylation of chemo-
kine receptors.
 
Materials and Methods
 
Cells.
 
Human polymorphonuclear neutrophils (21) and mono-
cytes were obtained from healthy donor blood packs. Neutrophils
were isolated from human blood by 3% dextran in PBS sedimen-
tation of Ficoll-Hypaque–generated pellets followed by hypotonic
lysis (0.2% NaCl) of contaminating red cells. Neutrophils were
 
.
 
95% pure by morphological criteria. Monocytes were purified
from Ficoll-Hypaque–generated mononuclear cells using MACS
 
Ò
 
CD14 microbeads (Miltenyi Biotec Inc., Auburn, CA) as per the
manufacturer’s instructions. The monocytes were 
 
.
 
90% pure by
nonspecific esterase staining.
 
Chemotaxis. 
 
In vitro chemotaxis was performed as described
previously (22). In brief, cells were incubated at 37
 
°
 
C with me-
dium, pertussis toxin (Sigma Chemical Co., St. Louis, MO) 500
ng/ml for 90 min, met-enkephalin (Sigma Chemical Co.) in
varying concentrations for 60 min, naloxone (Sigma Chemical
Co.) 10
 
2
 
8
 
 M for 10 min before met-enkephalin, or naloxone alone.
In other experiments, cells were preincubated with opiate recep-
tor-specific agonists or antagonists, or opiate incubation was pre-
ceded by pretreatment with the nitric oxide (NO) synthase inhib-
itor, 
 
l
 
-NMMA (
 
N
 
G
 
-monomethyl-
 
l
 
-arginine monoacetate [Sigma
Chemical Co.]). Chemotaxis was assessed in 48-well microchemo-
taxis chambers, using polyvinylpyrrolidone-free 5-
 
m
 
m pore size
membranes (Nucleopore; NeuroProbe, Cabin John, MD). Mi-
gration in response to met-enkephalin, morphine, chemokines,
or FMLP was allowed to continue for 90 min at 37
 
°
 
C in 5% CO
 
2
 
.
The membrane was removed, and the upper surface was washed
with PBS, scraped, fixed, and stained. The results are expressed as
chemotaxis index (mean number of cells per high power field for
chemoattractant dilution/mean number of cells per high power
field for medium) 
 
6
 
 SE from at least three separate experiments.
 
Intracellular Calcium Flux.
 
Human peripheral blood mono-
cytes and neutrophils were incubated at 10
 
7
 
/ml for 30 min at
room temperature in HBSS containing 0.1% BSA and 1 
 
m
 
M
Fura-2 (23). Cells were then washed in PBS and incubated with
met-enkephalin (10
 
2
 
9
 
 M) or morphine (10
 
2
 
6
 
 M) for 60 min,
with or without preincubation for 10 min in naloxone (10
 
2
 
8
 
 M).
The cells were washed and resuspended, and Fura-2 excitation
was assessed at 340 and 380 nm with detection at 510 nm in a lu-
minescence spectrometer using FL WinLab software (Perkin-
Elmer Corp., Norwalk, CT), after stimulation with opiate or
chemokine.
 
Assessment of Receptor Internalization Using Confocal Laser Micros-
copy.
 
Rat basophil leukemia cells (RBL2H3) stably transfected
to express CXCR1 were derived as described previously (24).
Transfected cells were untreated or incubated with IL-8 1 
 
m
 
g/ml
for 30 min or with met-enkephalin 10
 
2
 
9
 
 M for 3 h, fixed in 4%
paraformaldehyde, and centrifuged onto gelatin-coated slides.
Cells were permeabilized in 0.15% saponin before incubation for
60 min with an antiepitope mAb (12CA5; Boehringer Mann-
heim Biochemicals, Indianapolis, IN). After washing and incuba-
tion with FITC-labeled goat anti–mouse IgG, the cells were in-
cubated with DAPI (Sigma Chemical Co.) for 10 min. Slides
were examined using a confocal laser scanning microscope
(model 310; Carl Zeiss, Inc., Thornwood, NY). Nomarski, FITC
(488 nm, green), and DAPI (UV 364 nm, blue) images were pre-
pared for each specimen. Blue and green images were superim-
posed onto the Nomarski image.
 
Binding Assays.
 
Binding of chemokines to their receptors was
assessed using 1 ng/ml of 
 
125
 
I-labeled chemokine (NEN Research
Products, Boston, MA) in the presence of various concentrations
of unlabeled ligands or met-enkephalin (from equimolar to
1,000-fold excess), or after preincubation of the cells with met-
enkephalin for 60 min with or without pretreatment for 10 min
with naloxone. Cells at 10
 
7
 
/ml in RPMI 1640/1% BSA/25 mM
Hepes were incubated with ligands for 45 min at room tempera-
ture and pelleted through 10% sucrose; cell pellet–associated ra-
dioactivity was then determined in a 
 
g
 
-counter. Binding data
were analyzed using the computer program LIGAND.
 
Chemokine Receptor Phosphorylation.
 
Epitope-tagged FMLP re-
ceptor–transfected (25) and CXCR1-transfected RBL2H3 cells
were washed, then incubated in phosphate-free media for 3 h.
The cells were then labeled with 150 
 
m
 
Ci/7.5 
 
3
 
 10
 
6
 
 cells of
[
 
32
 
P]orthophosphate (NEN Research Products) for 90 min at
37
 
8
 
C before stimulation with native ligands for 5 min, met-enkepha-
lin 10
 
2
 
9
 
 M for 60 min, or naloxone 10
 
2
 
8
 
 M for 10 min before
met-enkephalin. Equivalent numbers of cells for each treatment
were lysed in RIPA buffer containing protease and phosphatase in-
hibitors. Epitope-tagged FMLP receptors and CXCR1 were im-
munoprecipitated as described previously (18) and run in 10%
SDS-polyacrylamide gels. The gels were dried and exposed to ra-
diographic film.
 
Results
 
Opiate-mediated Inhibition of Chemokine Chemotaxis.
 
We
sought initially to confirm previous reports (26, 27) that
opiate compounds, including met-enkephalin, are chemo-
tactic for monocytes and neutrophils. Preliminary studies
confirmed that phagocytes respond chemotactically, with a
chemotaxis index 2–2.5-fold higher than controls, to met-
enkephalin and morphine, with optimal activity at 10
 
2
 
9
 
and 10
 
2
 
6
 
 M, respectively. This chemotaxis was inhibited by
the opiate receptor antagonist naloxone
 
 
 
(data not shown).
To investigate the mechanism of chemotaxis, monocytes 
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were incubated for 90 min with pertussis toxin 500 ng/ml
before exposure to met-enkephalin in microchemotaxis
chambers. Fig. 1 demonstrates that the chemotactic activity
of met-enkephalin for monocytes was abolished completely
by pertussis toxin, suggesting association with the G
 
i
 
a
 
 sub-
class of G proteins.
The immunosuppressive and antiinflammatory effects of
opiates led us to assess the ability of met-enkephalin to
downregulate chemotaxis of monocytes in response to
macrophage-inflammatory protein (MIP)-1
 
a
 
 and mono-
cyte chemoattractant protein (MCP)-1. Preincubation of
freshly isolated human monocytes for 60 min with met-
enkephalin at concentrations of 10
 
2
 
15
 
–10
 
2
 
6
 
 M demon-
strated that the optimal concentration for inhibition of
MIP-1
 
a
 
 and MCP-1–induced chemotaxis was equivalent
to the optimal chemotactic dose, 10
 
2
 
9
 
 M (Fig. 2). This
concentration, as well as the peak chemotactic concentra-
tion of 10
 
2
 
6
 
 M for morphine, was used in subsequent inhi-
bition experiments.
We next assessed the effect of preincubation of mono-
cytes with met-enkephalin on chemotaxis in response to a
number of CC chemokines. MIP-1
 
a
 
, regulated upon acti-
vation, normal T expressed and secreted (RANTES), and
MCP-1 at their optimal concentrations of 50 ng/ml were
potent inducers of monocyte chemotaxis but were inhib-
ited by 82, 58, and 52%, respectively, by met-enkephalin
(Fig. 3 
 
A
 
). These inhibitory effects were prevented by pre-
incubation with 10
 
2
 
8
 
 M naloxone. In contrast, chemotaxis
in response to MIP-1
 
b
 
 was not inhibited by met-enkepha-
lin (Fig. 3 
 
A
 
). Although MIP-1
 
a
 
 and RANTES act through a
number of CC chemokine receptors, including CCR1,
CCR3, and CCR5, MIP-1
 
b
 
 acts principally through CCR5
(28). These data suggest that some but not all CC chemo-
kine receptors can be inhibited by met-enkephalin, and
that the degree of inhibition varies between receptors. Pre-
incubation of monocytes with met-enkephalin also had no
effect on chemotaxis induced by FMLP
 
 
 
(Fig. 3 
 
A
 
), indicat-
ing that the monocyte FMLP receptor, like its neutrophil
counterpart, is spared.
 
Preincubation of human neutrophils with met-enkepha-
lin 10
 
2
 
9
 
 M resulted in 61% inhibition of chemotaxis in-
duced by 100 ng/ml IL-8 (Fig. 3 
 
B
 
). Inhibition was re-
versed by the presence of 10
 
2
 
8
 
 M naloxone during the
incubation period, suggesting that this enkephalin-induced
effect was opiate receptor–mediated. Naloxone alone, al-
though thought to act as a partial agonist for opiate recep-
tors (29), was ineffective at inhibiting chemotaxis in response
to IL-8 (Fig. 3 
 
B
 
). Importantly, FMLP-induced chemotaxis
of neutrophils was not inhibited by preincubation with
met-enkephalin (Fig. 3 B), indicating that the opiate effect
does not apply to all chemoattractant STM receptors.
Opiate Receptor Specificity. To determine the potential
role of morphine in inhibiting chemokine effects and to
dissect opiate receptor specificity, monocytes were preincu-
bated with morphine and certain opiate receptor–specific
agonists, then tested for their chemotactic response to MIP-1a.
Like met-enkephalin, morphine caused significant inhibi-
tion (86%) of MIP-1a–induced chemotaxis of monocytes
(Fig. 4 A), which was reversed by naloxone. Since mor-
phine is thought to mediate its effects in monocytes primar-
ily through m3 receptors (30), we examined the response of
monocytes to the m opiate receptor–selective peptide
DAMGO ([D-ala2,N-me-phe-gly5(ol)]-enkephalin). Pre-
treatment with this compound at 1029 M also resulted in
significant inhibition of MIP-1a chemotaxis (76%; Fig. 4
Figure 1. Chemotactic response of human peripheral blood monocytes
to met-enkephalin and effect of pertussis toxin pretreatment. The results
are expressed as chemotaxis index (mean number of cells per high power field
for met-enkephalin dilution/mean number of cells per high power field for
medium) 6 SE from two separate experiments. *P ,0.05; **P ,0.01.
Figure 2. Inhibition of monocyte chemotaxis in response to MIP-1a
100 ng/ml and MCP-1 100 ng/ml, after pretreatment using met-enkephalin.
Results are expressed as percentage of chemotactic response of untreated
cells. Data from two experiments. *P ,0.05; **P ,0.01.320 Opiate Inhibition of Chemokines
A). Moreover, the d-selective agonist dermenkephalin at 5 3
1028 M inhibited MIP-1a chemotaxis by 52%, whereas the
k-selective agonist dynorphin A at 1028 M caused no signif-
icant inhibition (Fig. 4 A). Similar results were observed for
neutrophils: DAMGO and dermenkephalin inhibited IL-
8–induced chemotaxis by 50 and 34%, respectively, whereas
dynorphin A had no effect (data not shown). Together,
these results suggest that opiate-mediated inhibition of
chemokine-induced chemotaxis occurs through activation
of m and d but not k opiate receptors expressed on mono-
cytes and neutrophils.
To clarify opiate receptor specificity further, monocytes
and neutrophils were incubated with the m-specific antago-
nist CTOP (cys2, tyr3, orn5, pen7 amide) at 1027 M or the
d-selective antagonist naltrindole at 2 3 1028 M before
met-enkephalin. CTOP reversed 67% of the met-enkepha-
lin–induced inhibition of MIP-1a–induced monocyte chemo-
taxis, whereas naltrindole reversed 30% (Fig. 4 B), indicat-
ing a greater effect through m than through d opiate receptors
on monocytes. Combining these antagonists before met-
enkephalin treatment reversed completely the met-enkephalin
effect. Similarly, preincubation of neutrophils with the m
receptor antagonist CTOP and with the d antagonist nal-
trindole reversed 66 and 46% of the met-enkephalin–medi-
ated inhibition of IL-8–induced chemotaxis, respectively
(data not shown).
Intracellular Calcium Flux. In addition to their ability to
generate chemotaxis of leukocytes, chemokines induce in-
tracellular Ca21 fluxes in many responding cells. Met-
enkephalin and morphine were assessed for their ability to
induce changes in intracellular Ca21 concentration, and for
any activity in heterologously reducing chemokine–induced
Ca21 mobilization. There was no evidence of direct induc-
tion of Ca21 flux by met-enkephalin in monocytes, nor did
preincubation with varying concentrations of met-enkephalin
alter the Ca21 flux induced by activating doses of MIP-1a
(Fig. 5). Analysis of the effect of met-enkephalin on the
EC50 of MIP-1a demonstrated a Ca21 flux response at low
doses. Peak Ca21 flux occurred using 10 ng/ml MIP-1a,
and the EC50 was z2 ng/ml, with no significant difference
between untreated and met-enkephalin–pretreated monocytes
(data not shown). The chemokines IL-8, NAP-2, MCP-1,
MCP-3, and RANTES, and the chemoattractant FMLP,
were also assessed in neutrophils and monocytes, as appro-
priate, and their capacity to induce Ca21 flux was similarly
unaffected by met-enkephalin or morphine pretreatment
(data not shown).
CXCR1 Internalization. To determine if the ability of
opiates to inhibit chemokine-induced chemotaxis arises
through chemokine receptor internalization, epitope-
tagged CXCR1-transfected RBL2H3 cells (24) were ex-
amined by confocal laser microscopy. Initial experiments
Figure 3. (A) Effects of met-enkephalin on FMLP (fMLP) and CC chemokine–induced monocyte chemotaxis. (B) Effects of met-enkephalin on
IL-8– and FMLP (fMLP)-induced neutrophil chemotaxis. The results are expressed as chemotaxis index (mean number of cells per high power field for
chemokine dilution/mean number of cells per high power field for medium) 6 SE from at least three separate experiments. *P ,0.05; **P ,0.01.321 Grimm et al.
demonstrated that these cells responded chemotactically to
IL-8, and that this chemotactic effect was inhibited in a
naloxone-sensitive manner by met-enkephalin pretreat-
ment, confirming the presence of functional opiate recep-
tors (data not shown). After preincubation with IL-8 1 mg/
ml for 30 min, the transfected cells showed prominent in-
ternalization of CXCR1, but no internalization was seen in
response to preincubation for 60 min using met-enkephalin
1029 M (Fig. 6). Similar observations were made for CXCR2
on human neutrophils and CCR5 on human monocytes
(data not shown).
Chemokine Binding after Opiate Treatment. To confirm
the lack of receptor internalization in response to opiates,
we examined the ability of met-enkephalin to inhibit bind-
ing of CXC and CC chemokines to their specific recep-
tors. Using 125I-labeled chemokines and met-enkephalin on
fresh human neutrophils and monocytes, there was no evi-
dence in direct competition assays of binding of met-enkepha-
lin to receptors for IL-8, NAP-2, MCP-1, MCP-2, MCP-3,
MIP-1a, MIP-1b, or RANTES. Similarly, after preincu-
bation of cells with met-enkephalin for 60 min, there was
no impairment of chemokine binding (Fig. 7), suggesting
that chemokine receptor affinity and number were not
modulated by this duration of met-enkephalin treatment.
Therefore, the observed met-enkephalin effects on chemo-
tactic responses were not occurring at the level of chemo-
kine receptor binding of ligands.
Involvement of NO. Recent data suggest that morphine-
mediated effects in monocytes and neutrophils may be due
to the generation of NO (30). Monocytes treated with the
NO synthase inhibitor l-NMMA (NG-monomethyl-l-argi-
nine monoacetate) before incubation with opiates showed
no change in the opiate-induced inhibition of MIP-1a
chemotaxis, nor did the NO donor diethylamine dinitric
oxide (31) at 500 mM, which generates NO at a concentra-
tion  z104-fold higher than the inhibitory concentration
thought to be produced by morphine-stimulated mono-
cytes (30), reproduce the opiate effect (data not shown).
Thus, opiate-induced inhibition of chemokine effects is
not mediated by NO.
Phosphorylation of Chemoattractant Receptors. Since opiate
molecules, like chemokines, mediate their actions through
STM receptors, the possibility that inhibition of chemo-
kines occurred by a process of heterologous desensitization
was next examined. For technical reasons, analysis of
chemokine receptor phosphorylation in neutrophils and
monocytes was unsuccessful; in view of this, phosphoryla-
tion was examined in a receptor transfected cell system.
Epitope-tagged FMLP receptor–expressing and epitope-
tagged CXCR1-expressing RBL2H3 cells were incubated
in phosphate-free medium, then with [32P]orthophosphate.
They were then stimulated with FMLP 1026 M (for the
FMLP receptor–expressing cells), IL-8 500 ng/ml (for the
CXCR1-expressing cells), or met-enkephalin 1029 M. Af-
Figure 4. Effects of opiate receptor–specific agonists and antagonists on
chemokine-induced monocyte chemotaxis. (A) Effect on MIP-1a–induced
chemotaxis of monocytes, of preincubation with the k-specific agonist
dynorphin A, the d-specific agonist dermenkephalin, the m-specific ago-
nist DAMGO, and morphine. (B) Effect on MIP-1a–induced chemotaxis
of monocytes, of pretreating before met-enkephalin with the d-specific
antagonist naltrindole and the m-specific antagonist CTOP. *P ,0.05;
**P ,0.01.
Figure 5. Effect on Ca21 flux induced by MIP-1a 1 mg/ml in un-
treated monocytes or monocytes pretreated with met-enkephalin 10211
M, 1029 M, and 1027 M. Met-enkephalin 1029 M did not induce a Ca21
flux in these cells. Representative experiment of four similar experiments.322 Opiate Inhibition of Chemokines
ter whole cell lysis, chemoattractant receptors were immu-
noprecipitated and examined on SDS-polyacrylamide gels
exposed to radiographic film (18). The results demonstrate
that in addition to the expected phosphorylation of the
chemoattractant receptors induced by the native ligands,
CXCR1 was phosphorylated in response to met-enkepha-
lin (Fig. 8). This phosphorylation was inhibited by nalox-
one (Fig. 8). CXCR2 immunoprecipitated from retinoic
acid–differentiated U937 cells also was found to be phos-
phorylated after exposure of the cells to met-enkephalin
(data not shown). The FMLP receptor was not phosphory-
lated in response to met-enkephalin treatment (Fig. 8).
Discussion
This paper describes for the first time a plausible and in-
triguing mechanism by which opiates may mediate the im-
paired leukocyte function observed in drug abusers and in
animal models of opiate abuse. It also suggests the possibil-
ity of an immunomodulatory role for endogenous opiates
in controlling leukocyte recruitment. It confirms earlier
studies (26, 27) showing that opiate molecules can act di-
rectly, albeit weakly, as chemoattractants, and demonstrates
that this functional effect is pertussis toxin–sensitive, sug-
gesting coupling of opiate receptors in monocytes to the
Gia subclass of G proteins. Although this has been shown
for opiate responses in hippocampal slices (32) and m recep-
tor–transfected Jurkat cells (33), to our knowledge this is
the first analysis of G protein use by opiate receptors on na-
tive leukocytes.
The heterologous desensitization of chemokine responses
observed in these experiments has definite selectivity, since
the FMLP receptor is unaffected and CCR5 may also be
relatively spared, indicating that there is no generalized im-
pairment of cell motility. The intracellular controls that
generate this apparent selectivity remain to be clearly defined,
although sparing of the FMLP receptor in heterologous
phosphorylation processes has been observed previously
and may reflect the absence of protein kinase C phosphory-
lation sites in intracellular portions of the receptor (18). A
further clue to molecular mechanisms of opiate-induced
desensitization is suggested by the lack of inhibition of
chemokine-induced Ca21 flux and absence of chemokine
receptor internalization by opiates, despite both impairment of
the chemotactic response and enhancement of receptor
phosphorylation. These features imply a lower requirement
for G protein activation by chemokine receptors for Ca21
mobilization than for chemotaxis. Alternatively, by analogy
with studies examining cross-regulation among chemoat-
tractant receptors (34), there may be levels in addition to
receptor phosphorylation at which desensitization occurs.
Studies are planned to identify the roles of various receptor
kinases and intracellular receptor residues involved in the di-
vergent desensitization responses observed here.
The effects of met-enkephalin observed in monocytes
and neutrophils are mediated through m and d but not k
Figure 6. Absence of CXCR1
internalization in response to
pretreatment of epitope-tagged
CXCR1-transfected RBL2H3
cells with met-enkephalin. Trans-
fected cells were (A) untreated,
(B) incubated with IL-8 1 mg/ml
for 30 min, or with (C) met-
enkephalin 10-9 M for 3 h. Repre-
sentative micrographs from  .10
experiments are shown.
Figure 7. (A) Scatchard analysis of MIP-1a binding to untreated
monocytes, showing 5,356 binding sites per cell. After pretreatment of
monocytes with met-enkephalin 10-9 M for 60 min (B), the binding char-
acteristics of MIP-1a were unchanged, with 6,080 binding sites per cell
detected. Representative plots of two experiments. B/T, Bound/total. B/F,
Bound/free.323 Grimm et al.
opiate receptors. All three receptor types are known to be
expressed by leukocytes (11–15), and their differential abil-
ity to interact with chemokine receptors suggests the possi-
bility of using specific receptor agonists as potential antiin-
flammatory molecules. The lack of efficacy of k agonists in
inhibiting chemokine effects contrasts with the ability of k
receptor activation to inhibit replication of HIV-1 in mi-
croglial cells, the central nervous system equivalent of resi-
dent macrophages (15), suggesting divergence between
blood monocytes and tissue macrophages in opiate receptor
expression or responsiveness. The molecular mechanisms
of opiate receptor selectivity in chemokine receptor desen-
sitization remain to be elucidated. Although some opiate-
mediated, and specifically morphine-mediated, effects on
leukocytes appear to involve NO-dependent devices (30),
it is clear from our results that desensitization of chemokine
responses by m and d opiate receptor activation occurs in-
dependently of NO generation.
This study has broad implications for the inhibition of
leukocyte responses by opiate molecules, and indeed by
other apparently nonimmune mediators acting through
STM receptors. The data suggest a mechanism by which
opiates function as antiinflammatory or immunosuppressive
agents, by interfering with chemokine-induced directional
migration of inflammatory cells. That inhibition or absence
of chemokines can markedly suppress inflammatory reac-
tions has been demonstrated in several animal models of
disease by administration of neutralizing antibodies (35,
36), as well as in virally infected chemokine deletion mu-
tants (37). Therefore, exposure of leukocytes to opiates in
vivo may result in profoundly impaired host responses.
This may have direct clinical relevance, such as in the set-
ting of analgesia given in the presence of infectious or sur-
gical insults or in the intravenous drug user exposed to in-
fectious agents. However, this study may also have relevance
in the potential modulation of immune and inflammatory
responses due to endogenous opiate molecules, which
among other neuropeptides are known to be released by
cells of the immune system (38), and which may act as nor-
mal regulators of chemotaxis. These molecules also may
play a role in altering inflammatory responses in pathophys-
iological states such as septic shock (39). Moreover, the
finding of opiate-induced neuroimmunomodulation of
chemokine function raises the prospect that other neuroen-
docrine mediators, acting through STM receptors, might
operate through similar mechanisms, a possibility we are
currently investigating.
Figure 8. Phosphorylation of
chemoattractant receptors in response
to native ligands, met-enkephalin, or
naloxone and met-enkephalin. Equiv-
alent numbers of cells for each treat-
ment were analyzed. Lane 1, Un-
treated (unt); lane 2, native ligand
(FMLP [fMLP] 10-7 M or IL-8 1
mg/ml); lane 3, met-enkephalin
(met-enk); lane 4, naloxone plus met-
enkephalin (nal 1 met-enk). Repre-
sentative of three experiments.
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